De Botton et al. very recently provided a new evaluation of the data on the effect of enasidenib on overall survival of refractory/relapsing AML patients, providing support to the view that this IDH2 inhibitor may prolong the survival of patients with refractory/relapsing mutant IDH2 AML, compared to the standard of care [148]. Here, IDH2 is linked to acute myeloid leukemia.